Excerpts

The distribution of race between the group of subjects with HCC recurrence showed a trend toward a higher proportion of White and a lower proportion of Black patients; however, this was not a statistically significant difference.

19.7 months; HR 0.80; p = 0.018) and a favorable trend in OS (54.3 vs. 48.3 months) compared to those receiving the NACT-first sequence [ 17 ].

Patients with a Sister Mary Joseph nodule showed a trend toward better survival outcomes.

Compared with MTAP wild-type tumors (median 63 years, IQR 55–69), patients with MTAP deletion showed a trend toward older age; however, this difference did not reach statistical significance (Wilcoxon rank-sum test, p = 0.069).

Although the majority of patients in the IOM cohort have an age of menarche at or below twelve, the risk class sub-analysis within the two categories (≤12 and >12) does not reveal a clear trend ( Figure 3 B).

In our study, stratification by FIGO stage showed a trend toward worse prognosis for G-EAC compared with usual-type endocervical adenocarcinoma, though not statistically significant, likely due to limited follow-up and sample size.

Among the remaining predictors, age showed a limited and element-specific effect, reaching borderline significance only for Mg (B = 0.77, 95% CI: 0.00 to 1.54), while confidence intervals for most other elements crossed zero.

Higher-grade tumors were associated with increased levels of Ca, P, Mg, and Mn, while Na and K showed a decreasing trend with tumor progression.

Pb showed an increasing trend after menopause, with higher values in postmenopausal patients, reaching significance in some comparisons (notably in A and C).

HRQoL data from the ASCEMBL trial comparing asciminib to bosutinib in patients with CML-CP previously treated with ≥2 TKIs showed a trend of improvement in the MDASI-CML and EQ-5D-5L scores in the asciminib arm, including fatigue, whereas there was a worsening of gastrointestinal symptoms in the bosutinib arm.

Although a numerical trend toward shorter PFS was observed with worsening LIPI categories in our cohort, this difference did not reach statistical significance.

Male sex showed a trend toward poorer OS and DFS.

In the present study, no significant relationship was found between the basic clinical and pathological parameters and the presence of central fibrosis/hyalinization area, except for a borderline significant trend toward less frequent occurrence in higher-grade tumors.

Leukaemia: The excess of leukaemia in parents in our study who were assumed not to have a germline RB1 mutation has no obvious explanation and, though statistically highly significant, may be due to chance.

Alterations in DNA damage response pathways and apoptosis/immune regulatory mechanisms also showed a trend toward enrichment in SS, with the latter observed only in SS tumors (4% vs. 0%), albeit at low frequency.

A significant reduction in SALL1 mRNA was observed in grade 3 (poorly differentiated) tumors, whereas grade 1 (well differentiated) and 2 (moderately differentiated) showed a decreasing trend without statistical significance.

In the AML19 study, AML patients were randomized to receive Tludarabine, Cytarabine, Idarubicin, and G-CSF (FLAG-IDA) or DA (Daunorubicin/Cytarabine): relapse rate (RR) was significantly lower with FLAG-IDA than with DA (three-year RR 26% or 68%, respectively), and there was a clear trend of improved OS for patients with FLAG-IDA compared to DA (three-year OS 66% vs. 37%, respectively) [ 28 ].

Overall survival of these patients was similar across the different KMT2A translocations, including those generating KMT2A/MLLT3 fusion; however, t(9;11)(p21.3;q23.3)/ KMT2A::MLLT3 AML had an almost significant improvement of RFS compared to other KMT2A translocations [ 25 ].

With respect to DFS, the later cohort showed a trend toward improvement, although the difference was not statistically significant (log-rank p = 0.176).

Additionally, Kaplan–Meier analysis showed a trend toward reduced overall survival in tumors with elevated PI3K–AKT pathway activity compared with AKT-low tumors, although this did not reach statistical significance (log-rank p = 0.093; Figure 7 C).

Most cases were open (66.4%); however, there was an overall trend towards increased robotics, as only 58% of cases were open from 2020 to 2023.

Additionally, the Rs-2018 regimen showed a trend towards improved survival in both EFS and OS compared with the Rs-99 regimen, particularly in the high-risk subgroup, although it did not reach statistical significance.

Instead, a descriptive analysis of the data revealed distinct trends: DPE appeared to offer a favorable trend for tumor control in extremity tumors.

The logistic regression showed a trend towards a reduced rate of postoperative complications after neoadjuvant FLOT treatment, although this was not statistically significant.

Moreover, this regimen showed a strong trend that approached significance in terms of median RFS (4.5 vs. 2.5 years; HR 0.85; p 0.065).